Genor Biopharma Announces Major Merger

Genor Biopharma Holdings Limited (HK:6998) has released an update.

Genor Biopharma Holdings Limited has announced a significant merger with the ‘Target’ company, resulting in the Target becoming a wholly-owned subsidiary, with substantial issuance of consideration shares to Target shareholders. The merger is contingent on specific terms and conditions, and aims to enhance the company’s governance structure through the establishment of a Joint Steering Committee. Additionally, a management agreement for CDK4/6i has been established between the company and the Target to manage all related matters during the transition.

For further insights into HK:6998 stock, check out TipRanks’ Stock Analysis page.